Sugi Predict

Sugi Predict / Compounds / SCHEMBL2483052

SCHEMBL2483052

SCHEMBL2483052

CC(C)C=NNc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOX1 Q9Y5S8 2/20 0.52
▸ MAPT P10636 9/20 0.44
▸ MEN1 O00255 6/20 0.44
▸ KMT2A Q03164 6/20 0.44
▸ GAA P10253 5/20 0.44
▸ ALDH1A1 P00352 5/20 0.44
▸ HPGD P15428 4/20 0.44
▸ RAB9A P51151 4/20 0.44
▸ LMNA P02545 3/20 0.44
▸ GFER P55789 1/20 0.44
▸ TDP1 Q9NUW8 4/20 0.43
▸ SMN1; SMN2 Q16637 4/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ TSHR P16473 2/20 0.39
▸ CYP1A1 P04798 1/20 0.39
▸ CYP1B1 Q16678 1/20 0.39
▸ SENP7 Q9BQF6 2/20 0.39
▸ GPR39 O43194 1/20 0.38
▸ MAOA P21397 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13664138 1.00 NOX1 (0.52) NOX1MAPTMEN1KMT2AGAA
SCHEMBL2483049 1.00 NOX1 (0.52) NOX1MAPTMEN1KMT2AGAA
SCHEMBL3278077 0.83 NOX1 (0.48) NOX1MAPTMEN1KMT2AGAA
SCHEMBL11714851 0.82 MAPT (0.50) NOX1MAPTMEN1KMT2AGAA
SCHEMBL11673957 0.81 NPC1 (0.47) MAPTMEN1KMT2AGAAALDH1A1
SCHEMBL11673952 0.81 NPC1 (0.47) MAPTMEN1KMT2AGAAALDH1A1
SCHEMBL11674569 0.80 NPC1 (0.55) MAPTMEN1KMT2AGAAALDH1A1
SCHEMBL13664139 0.80 NOX1 (0.46) NOX1MAPTMEN1KMT2AGAA
SCHEMBL11674567 0.80 NPC1 (0.55) MAPTMEN1KMT2AGAAALDH1A1
SCHEMBL11213002 0.77 NOX1 (0.43) NOX1MAPTMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629289-B2 Method for the preparation of 1-acetyl-6-amino-3,3-dimethyl-2,3-dihydroindole AMGEN INC. (US) 2014-01-14 — — US claimed
US-20120136163-A1 Method for the Preparation of 1-Acetyl-6-Amino-3,3-Dimethyl-2,3-Dihydroindole AMGEN INC. (US) 2012-05-31 — — US claimed
EP-2376448-A2 IMPROVED METHOD FOR THE PREPARATION OF 1-ACETYL-6-AMINO-3,3-DIMETHYL-2,3-DIHYDROINDOLE Amgen, Inc (US) 2011-10-19 — — EP claimed
WO-2010071828-A2 IMPROVED METHOD FOR THE PREPARATION OF 1-ACETYL-6-AMINO-3,3-DIMETHYL-2,3-DIHYDROINDOLE AMGEN INC. (US) 2010-06-24 — — WO claimed
US-20210024539-A1 COMPOUNDS AS MODULATORS OF TLR2 SIGNALING NEUROPORE THERAPIES, INC. (US) 2021-01-28 — — US disclosed
US-20200308163-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING NEUROPORE THERAPIES, INC. (US) 2020-10-01 — — US disclosed
WO-2020198368-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING NEUROPORE THERAPIES, INC. (US) 2020-10-01 — — WO disclosed
WO-2019191189-A1 COMPOUNDS AS MODULATORS OF TLR2 SIGNALING NEUROPORE THERAPIES, INC. (US) 2019-10-03 — — WO disclosed
US-8629289-B2 Method for the preparation of 1-acetyl-6-amino-3,3-dimethyl-2,3-dihydroindole AMGEN INC. (US) 2014-01-14 — — US disclosed
US-8629289-B2 Method for the preparation of 1-acetyl-6-amino-3,3-dimethyl-2,3-dihydroindole AMGEN INC. (US) 2014-01-14 — — US disclosed
US-8202879-B2 Quinazoline derivatives having tyrosine kinase inhibitory activity SHIONOGI & CO., LTD. (JP) 2012-06-19 — — US disclosed
US-20120136163-A1 Method for the Preparation of 1-Acetyl-6-Amino-3,3-Dimethyl-2,3-Dihydroindole AMGEN INC. (US) 2012-05-31 — — US disclosed
CN-101607947-B Preparation method of derivatives of tetrahydro triazine UNIV ZHEJIANG 2011-08-24 — — CN disclosed
WO-2010071828-A2 IMPROVED METHOD FOR THE PREPARATION OF 1-ACETYL-6-AMINO-3,3-DIMETHYL-2,3-DIHYDROINDOLE AMGEN INC. (US) 2010-06-24 — — WO disclosed
WO-2010071828-A2 IMPROVED METHOD FOR THE PREPARATION OF 1-ACETYL-6-AMINO-3,3-DIMETHYL-2,3-DIHYDROINDOLE AMGEN INC. (US) 2010-06-24 — — WO disclosed
CN-101607947-A A kind of preparation method of derivatives of tetrahydro triazine UNIV ZHEJIANG (CN) 2009-12-23 — — CN disclosed
US-20090143414-A1 Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity SHIONOGI & CO., LTD. (JP) 2009-06-04 — — US disclosed
US-4094906-A INSECTICIDES AND MITICIDES THE UPJOHN COMPANY (US) 1978-06-13 — — US disclosed
US-4008217-A HERBICIDE THE UPJOHN COMPANY (US) 1977-02-15 — — US disclosed
US-3943132-A Process for the preparation of hydrazones PRODUITS CHIMIQUES UGINE KUHLMANN (FR) 1976-03-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143414-A1 Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity ERBB2, EGFR, ABL1 NOX1 1573/4885MAPT 4100/4885MEN1 3302/4885
US-20200308163-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING TLR3, TLR6, TLR4 NOX1 1995/4885MAPT 100/4885MEN1 4871/4885
US-20120136163-A1 Method for the Preparation of 1-Acetyl-6-Amino-3,3-Dimethyl-2,3-Dihydroindole AANAT, INMT, AADAT NOX1 3103/4885MAPT 928/4885MEN1 1108/4885
US-20210024539-A1 COMPOUNDS AS MODULATORS OF TLR2 SIGNALING TLR2, TLR4, TLR3 NOX1 2623/4885MAPT 237/4885MEN1 4870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.